With Costco Down 7% From Its All-Time High, Could Buying Now Set You Up for Life?

Costco trades at a steep 52.2x earnings multiple after a 688% total return over the past 10 years, with shares still about 7% below their February 2025 peak. The article argues the company remains high quality but has limited upside from a $270 billion fiscal 2025 sales base and is better kept on a watchlist until a pullback. Long-term growth remains intact, including a plan to open 30-plus net new warehouses annually and a 189% dividend increase over the past decade.

Analysis

The market is still treating COST like a bond-proxy compounder, but at >50x earnings the next leg of returns likely depends more on multiple support than fundamental acceleration. That creates an asymmetric setup where any deceleration in traffic, basket mix, or membership renewal cadence can trigger a sharp de-rating even if operating results remain strong. In other words, the stock’s main risk is not a business miss but a narrative miss: investors are paying for uninterrupted perfection, and that is rarely durable in a mature retail format.

Second-order, the real competitive issue is capital intensity discipline. If Costco continues adding 30+ net warehouses annually, it reinforces the moat, but it also pushes the business further down the curve where each incremental unit has to defend an increasingly large revenue base. That makes the stock less sensitive to near-term same-store sales and more sensitive to long-duration assumptions around unit economics, membership monetization, and reinvestment returns.

The contrarian angle is that the bearish case may already be broadly owned, yet still underpriced in timing terms. COST can stay expensive for a long time if the market keeps rewarding quality and defensiveness, so this is less a short candidate on valuation alone and more a candidate for patience via options or a relative-value structure. The cleanest catalyst for downside is not macro weakness per se, but a period of slower warehouse growth, softer consumer trade-down tailwinds, or any evidence that margin expansion is peaking.

BRK.B is the more interesting adjacent beneficiary if investors rotate from paying up for high-quality retail compounding into a diversified capital allocator with less single-name execution risk. NVDA and INTC are only tangentially affected via the article’s broader “quality at any price” framing, but the stronger signal is sentiment: when investors start questioning premium valuation in one iconic compounder, it can spill over into other crowded quality trades.

Key Decisions for Investors

• Avoid initiating new long COST here; if already long, hedge with 1-3 month put spreads to protect against a 10-15% de-rating if growth guidance softens.
• Pair trade: long BRK.B / short COST for 3-6 months, betting that capital-light conglomerate quality is mispriced versus a retail multiple that leaves little room for execution slip.
• For tactical downside exposure, buy COST put spreads on any post-earnings strength; the risk/reward is best when implied volatility is compressed and expectations are highest.
• If looking for a long-only entry, wait for a 12-18% pullback or a forward P/E reset into the low-40s, where the valuation starts to embed less perfection.